[1]贾红红,李红莉,孙丽华.慢性肾脏病患者血清BMP2，BMP7水平表达与左心室肥厚的相关性研究[J].现代检验医学杂志,2024,39(06):179-184.[doi:10.3969/j.issn.1671-7414.2024.06.031]
　JIA Honghong,LI Hongli,SUN Lihua.Study on Association between Serum BMP2, BMP7 Level and Left Ventricular Hypertrophy among Chronic Kidney Disease Patients[J].Journal of Modern Laboratory Medicine,2024,39(06):179-184.[doi:10.3969/j.issn.1671-7414.2024.06.031]
点击复制

慢性肾脏病患者血清BMP2，BMP7水平表达与左心室肥厚的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年06期
页码:
179-184
栏目:
论著
出版日期:
2024-11-15

文章信息/Info

Title:
Study on Association between Serum BMP2, BMP7 Level and Left Ventricular Hypertrophy among Chronic Kidney Disease Patients
文章编号:
1671-7414（2024）06-179-06
作者:
贾红红; 李红莉; 孙丽华
（延安市人民医院肾内科，陕西延安 716000）
Author(s):
JIA Honghong;  LI Hongli;  SUN Lihua
（Department of Nephrology, Yan’an People’s Hospital, Shaanxi Yan’an 716000, China）
关键词:
慢性肾脏病; 骨形成蛋白2; 骨形成蛋白7; 左心室肥厚
分类号:
R692；R392.11
DOI:
10.3969/j.issn.1671-7414.2024.06.031
文献标志码:
A
摘要:
目的 探讨慢性肾脏病（chronic kidney disease，CKD）患者血清骨形成蛋白2（bone morphogenetic protein 2，BMP2）、骨形成蛋白7（bone morphogenetic protein 7，BMP7）水平表达与左心室肥厚（left ventricular hypertrophy，LVH）的相关性。方法 收集2019 年6 月～ 2023 年6 月延安市人民医院收治的93 例CKD 患者为CKD 组，根据是否并发LVH 分为LVH 组（n=34）和非LVH 组（n=59）。并于同期选取60 例健康体检者为对照组。收集各组临床资料并采用酶联免疫吸附法（ELISA）检测血清BMP2 和BMP7 水平，Spearman 秩相关分析血清BMP2 和BMP7 与CKD分期的关系。Logistic 回归分析CKD 患者并发LVH 的影响因素，绘制ROC 曲线评估血清BMP2，BMP7 和两指标联合检测对LVH 的诊断价值。结果 CKD 组血清BMP2（106.09±19.34 pg/ml）高于对照组（83.76±15.27 pg/ml），BMP7（15.16±4.92 pg/ml）低于对照组（26.53±5.80 pg/ml），差异具有统计学意义（t=7.559，13.002，均P<0.05）。CKD I 期，II 期，III 期，IV 期和V 期患者血清BMP2 水平依次升高[90.32±6.04，98.56±6.63，110.32±7.49，121.13±7.82，131.81±7.97 pg/ml）， 血清BMP7 水平依次降低（20.06±2.79，17.01±2.22，13.34±2.18，11.20±2.01，9.35±2.09pg/ml），差异具有统计学意义（F=19.863，11.567，均P<0.05）。血清BMP2 与CKD 分期呈正相关（r= 0.592，P<0.05），血清BMP7 与CKD 分期呈负相关（r= -0.603，P<0.05）。BMP2 是LVH 独立危险因素[OR（95%CI）：1.640（1.317 ～ 2.043），P<0.05]；BMP7 升高是CKD 患者并发LVH 的保护因素[OR（95%CI）：0.521（0.349 ～ 0.779）P<0.05]。血清BMP2，BMP7 对LVH 均有诊断价值，AUC（95%CI）分别为0.782（0.719 ～ 0.832）和0.791（0.726 ～ 0.859），二者联合检测的AUC（95%CI）为0.873（0.812 ～ 0.930），诊断价值大于单一指标（Z=2.357，2.027，均P<0.05）。结论 CKD 患者BMP2 异常升高，BMP7 异常下降，两指标异常表达与CKD 病情及LVH 相关，早期联合检测可作为诊断LVH 的指标。
Abstract:
Objective To explore the expression of serum bone morphogenetic protein 2 (BMP2)，bone morphogenetic protein 7 (BMP7) level and its association with left ventricular hypertrophy (LVH) among patients with chronic kidney disease (CKD). Methods A total of 93 CKD patients admitted to Yan’an People’s Hospital from June 2019 to June 2023 were collected as CKD group, divided into LVH group (n=34) and non-LVH group (n=59) according to whether concurrence was combined with LVH. A total of 60 healthy volunteers were selected as control group in the same period. The clinical data were collected and serum BMP2 and BMP7 levels were detected by enzyme-linked immunosorbent assay (ELISA). The association between serum BMP2, BMP7 and CKD stage was analyzed by Spearman’s rank correlation analysis. Logistic regression analyze was performed to analyze the influencing factors of CKD patients with concomitant LVH. ROC curves were plotted to assess the diagnostic value of serum BMP2, BMP7 on LVH. Results Serum BMP2 (106.09±19.34 pg/ml) in CKD group was higher than that in control group (83.76±15.27 pg/ml), and serum BMP7 (15.16±4.92 pg/ml) in CKD group was lower than that in control group (26.53±5.80 pg/ml), the differences were statistically significant (t=7.559, 13.002, all P<0.05). Serum BMP2 was sequentially increased in patients with CKD stages I, II, III, IV and V(90.32±6.04, 98.56±6.63, 110.32±7.49, 121.13±7.82, 131.81±7.97 pg/ml), and serum BMP7 was sequentially decreased (20.06±2.79, 17.01±2.22, 13.34±2.18, 11.20±2.01, 9.35±2.09 pg/ml), and the differences were statistically significant (F=19.863,11.567, all P<0.05). Serum BMP2 was positively correlated with CKD stage (r= 0.592, P<0.05), while serum BMP7 was negatively correlated with CKD stage (r= -0.603, P<0.05). BMP2 was an independent risk factor for LVH in CKD patients [OR（95%CI）: 1.640 （1.317 ～ 2.043）, P<0.05]. BMP7 was a protective factor for LVH in CKD patients [OR（95%CI）: 0.521（0.349 ～ 0.779）, P<0.05]. Both serum BMP2 and BMP7 had diagnostic value for LVH with AUC（95%CI）of 0.782（0.719 ～ 0.832）and 0.791 （0.726 ～ 0.859）, respectively. The AUC（95%CI） of the combination of two indicators was 0.873 (0.812 ～ 0.930), which was greater than that of single indicator (Z=2.357, 2.027, all P<0.05). Conclusion BMP2 is abnormally elevated and BMP7 is abnormally decreased in CKD patients, and the abnormal expression of two indicators is associated with CKD disease and LVH. Early combined detection of two indexes can be used as an indicator for diagnosing LVH.

参考文献/References:

[1] Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease [J]. Kidney International, 2022, 102(5S): S1-S127.
[2] 杨雄, 尹爱萍. 慢性肾脏病患者血液中FGF23,TNF-α, RANTES 和IL-12 检测水平的相关性研究[J]. 现代检验医学杂志, 2020, 35(1): 25-28. YANG Xiong, YIN Aiping. Correlation between FGF23, TNF-α, RANTES and IL-12 levels in the bloodof patients with chronic kidney disease [J]. Journal of Modern Laboratory Medicine, 2020, 35(1): 25-28.
[3] ZOCCALI C, MALLAMACI F, ADAMCZAK M, et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association[J]. Cardiovascular Research, 2023, 119(11): 2017-2032.
[4] NARDI E, MUL? G, GIAMMANCO A, et al. Left ventricular hypertrophy in chronic kidney disease: a diagnostic criteria comparison [J]. Nutrition, Metabolism,and Cardiovascular Diseases, 2021, 31(1): 137-144.
[5] KADHIM M M, BOKOV D O, ANSARI M J, et al. Bone morphogenetic protein (BMP)-modified graphene oxidereinforced polycaprolactone-gelatin nanofiber scaffolds for application in bone tissue engineering[J]. Bioprocess and Biosystems Engineering, 2022, 45(6): 981-997.
[6] ALUGANTI NARASIMHULU C, SINGLA D K. The role of bone morphogenetic protein 7 (BMP-7) in inflammation in heart diseases[J]. Cells, 2020, 9(2): 280.
[7] MANZANO-LISTA F J, SANZ-G?MEZ M,GONZ?LEZ-MORENO D, et al. Imbalance in bone morphogenic proteins 2 and 7 is associated with renal and cardiovascular damage in chronic kidney disease[J]. International Journal of Molecular Sciences,2022, 24(1): 40.
[8] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组. 慢性肾脏病筛查诊断及防治指南[J]. 中国实用内科杂志, 2017, 37(1): 28-34. Expert Group on Early Detection, Diagnosis and Treatment System Construction of Chronic Kidney Disease in Shanghai. Guideline for screening, diagnosis, prevention and treatment of chronic kidney disease[J]. Chinese Journal of Practical Internal Medicine, 2017, 37(1): 28-34.
[9] 孙宁玲, CHEN JAW- WEN , 王继光, 等. 亚洲高血压合并左心室肥厚诊治专家共识[J]. 中华高血压杂志, 2016, 24(7): 619-627, 600. SUN Ningling, CHEN J W, WANG Jiguang, et al. Consensus of diagnosis and treatment of hypertension combined with left ventricular hypertrophy in Asia[J]. Chinese Journal of Hypertension, 2016, 24(7): 619-627, 600.
[10] 张帅, 谢娟, 张译元, 等. 慢性肾脏病患者血清NGAL, OPN 及MMP9 水平与左心室肥厚的关系[J].医学研究杂志, 2022, 51(11): 173-177, 148. ZHANG Shuai, XIE Juan, ZHANG Yiyuan, et al. Relationship between the serum levels of neutrophil gelatinase-associated lipocalin(NGAL),osteopontin(OPN) and matrix metalloproteinase 9(MMP9)with left ventricular hypertrophy in patients with chronic kindey disease[J]. Journal of Medical Research, 2022, 51(11): 173-177, 148.
[11] GBD Chronic Kidney Disease Collaboration. Global,regional, and national burden of chronic kidney disease,1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet, 2020, 395(10225): 709-733.
[12] 王凯. 血清25 羟维生素D 水平与慢性肾脏病患者左心室肥厚的相关性分析[J]. 河南医学研究, 2021,30(17): 3134-3136. WANG Kai. Association between serum 25-hydroxyvitamin D level and left ventricular hypertrophy in patients with chronic kidney disease[J]. Henan Medical Research, 2021, 30(17): 3134-3136.
[13] 何田田. 血清25 羟维生素D 水平与慢性肾脏病4 ~ 5 期患者左心室肥厚的相关性[J]. 慢性病学杂志, 2023, 24(7): 1032-1034. HE Tiantian. The correlation between serum 25-hydroxyvitamin D levels and left ventricular hypertrophy in patients with stage 4-5 chronic kidney disease[J]. Chronic Pathematology Journal, 2023,24(7): 1032-1034.
[14] YILDIZ M, OKTAY A A, STEWART M H, et al. Left ventricular hypertrophy and hypertension[J]. Progress in Cardiovascular Diseases, 2020, 63(1): 10-21.
[15] 赵智凝, 武易, 刘芳, 等. 慢性肾病患者血清Klotho,HE4,UMOD 表达水平与疾病预后的相关性研究[J]. 现代检验医学杂志, 2021, 36(2): 28-31, 56. ZHAO Zhining, WU Yi, LIU Fang, et al. Study on the relationship between the expression level of klotho,HE4 and uromodulin and the development of chronic kidney disease[J]. Journal of Modern Laboratory Medicine, 2021, 36(2): 28-31, 56.
[16] 叶天宇, 郝琪, 毕宏生, 等. 骨形成蛋白及其信号通路在近视发病机制中作用的研究进展[J]. 眼科新进展, 2023, 43(7): 575-579. YE Tianyu, HAO Qi, BI Hongsheng, et al. Research progress on the role of bone morphogenetic proteins and their signaling pathways in the pathogenesis of myopia[J]. Recent Advances in Ophthalmology, 2023,43(7): 575-579.
[17] 陆涛, 魏泽红, 王熠成, 等. 骨形成蛋白2 基因多态性与冠脉钙化相关性研究[J]. 重庆医科大学学报,2023, 48(3): 248-254. LU Tao, WEI Zehong, WANG Yicheng, et al. Correlation between bone morphogenetic protein 2 gene polymorphism and coronary artery calcification[J]. Journal of Chongqing Medical University, 2023, 48(3): 248-254.
[18] NAKAGAWA Y, IKEDA K, AKAKABE Y, et al. Paracrine osteogenic signals via bone morphogenetic protein-2 accelerate the atherosclerotic intimal calcification in vivo[J]. Arteriosclerosis, Thrombosis,and Vascular Biology, 2010, 30(10): 1908-1915.
[19] 颜建云, 周芹, 陈燕玲, 等. BMP2 参与Decorin 诱导的血管平滑肌细胞钙化[J]. 中山大学学报(医学科学版), 2014, 35(3): 352-357. YAN Jianyun, ZHOU Qin, CHEN Yanling, et al. BMP2 mediates decorin-induced vascular smooth muscle cell calcification[J]. Journal of Sun Yat-Sen University(Medical Sciences), 2014, 35(3): 352-357.
[20] SAMPATH T K, REDDI A H. Discovery of bone morphogenetic proteins - a historical perspective [J]. Bone, 2020, 140:115548.
[21] VERNOUSFADERANI E K, AKHTARI N, REZAEI S, et al. Resveratrol and colorectal cancer:a molecular approach to clinical researches[J]. Current Topics in Medicinal Chemistry, 2021, 21(29): 2634-2646.
[22] JIMI E, FEI Huang, NAKATOMI C. NF-κB signaling regulates physiological and pathological chondrogenesis[J]. International Journal of Molecular Sciences, 2019, 20(24): 6275.
[23] 徐建男, 王淑明, 张建新, 等. 维持性血液透析患者血清GRP78, BMP2 水平及其与血管钙化的相关性[J]. 中国血液净化, 2023, 22(4): 254-258. XU Jiannan, WANG Shuming, ZHANG Jianxin, et al. The levels of serum GRP78 and BMP2 in maintenance hemodialysis patients and their correlation with vascular calcification[J]. Chinese Journal of Blood Purification, 2023, 22(4): 254-258.
[24] SMITH C, DU TOIT R, OLLEWAGEN T. Potential of bone morphogenetic protein-7 in treatment of lupus nephritis: addressing the hurdles to implementation[J]. Inflammopharmacology, 2023, 31(5): 2161-2172.

相似文献/References:

[1]王洁敏,向 芃,顾乐怡.不同预处理方法对提取尿液脱落细胞mRNA质量的影响[J].现代检验医学杂志,2016,31(04):125.[doi:10.3969/j.issn.1671-7414.2016.04.035]
　WANG Jie-min,XIANG Peng,GU Le-yi.Effects of Different Pretreatment Methods on mRNA Quality and Quantity of Exfoliated Urinary Cells[J].Journal of Modern Laboratory Medicine,2016,31(06):125.[doi:10.3969/j.issn.1671-7414.2016.04.035]
[2]肖传宇,王 宁,王小艳,等.血清胰岛素与慢性肾脏病的相关研究及其应用价值[J].现代检验医学杂志,2017,32(01):109.[doi:10.3969/j.issn.1671-7414.2017.01.030]
　XIAO Chuan-yu,WANG Ni,WANG Xiao-yan,et al.Correlation of Serum Insulin and Chronic Kidney Disease and Its Application Value[J].Journal of Modern Laboratory Medicine,2017,32(06):109.[doi:10.3969/j.issn.1671-7414.2017.01.030]
[3]卢美红,杨春兰,景蓉蓉,等.血清人附睾蛋白4表达与慢性肾脏病的相关性研究[J].现代检验医学杂志,2017,32(02):75.[doi:10.3969/j.issn.1671-7414.2017.02.020]
　LU Mei-hong,YANG Chun-lan,JING Rong-rong,et al.Study on Association with Expression in Patients with Chronic Kidney Disease[J].Journal of Modern Laboratory Medicine,2017,32(06):75.[doi:10.3969/j.issn.1671-7414.2017.02.020]
[4]杨 雄,尹爱萍.慢性肾脏病不同分期患者血清多项骨代谢指标变化与成纤维细胞生长因子23的相关性分析[J].现代检验医学杂志,2019,34(04):58.[doi:10.3969/j.issn.1671-7414.2019.04.014]
　YANG Xiong.,YIN Ai-ping.Analysis of the Correlation between Serum Bone Metabolism and Fibroblast Growth Factor 23 in Patients with Chronic Kidney Disease at Different Stages[J].Journal of Modern Laboratory Medicine,2019,34(06):58.[doi:10.3969/j.issn.1671-7414.2019.04.014]
[5]杨 雄,尹爱萍.慢性肾脏病患者血液中FGF23,TNF-α,RANTES 和IL-12 检测水平的相关性研究[J].现代检验医学杂志,2020,35(01):25.[doi:10.3969/j.issn.1671-7414.2020.01.007]
　YANG Xiong,YIN Ai-ping.Correlation between FGF23,TNF-α, RANTES and IL-12 Levels in the Bloodof Patients with Chronic Kidney Disease[J].Journal of Modern Laboratory Medicine,2020,35(06):25.[doi:10.3969/j.issn.1671-7414.2020.01.007]
[6]曹　雷a,汪隆海a,周　梅a,等.慢性肾心综合征患者血清9项心衰标志物水平联合检测的实验诊断价值研究[J].现代检验医学杂志,2021,36(05):90.[doi:10.3969/j.issn.1671-7414.2021.05.020]
　CAO Leia,WANG Long-haia,ZHOU Meia,et al.Study on Experimental Diagnostic Value for Combined Detection of 9 HeartFailure Markers in Serum of Patients with Chronic Renal Heart Syndrome[J].Journal of Modern Laboratory Medicine,2021,36(06):90.[doi:10.3969/j.issn.1671-7414.2021.05.020]
[7]王若霜,冷彦飞,袁飞远.mitoTEMPO 通过调控线粒体自噬对慢性肾脏病模型大鼠足细胞损伤的保护作用研究[J].现代检验医学杂志,2024,39(05):22.[doi:10.3969/j.issn.1671-7414.2024.05.005]
　WANG Ruoshuang,LENG Yanfei,YUAN Feiyuan.Study on the Protective Effect of mitoTEMPO on Podocyte Injury in Rat Models with Chronic Kidney Disease by Modulating Mitochondrial Autophagy[J].Journal of Modern Laboratory Medicine,2024,39(06):22.[doi:10.3969/j.issn.1671-7414.2024.05.005]

备注/Memo

备注/Memo:
基金项目：陕西省自然科学基础研究计划项目（2018JM1056）。
作者简介：贾红红（1992-），女，硕士研究生，主治医师，研究方向：肾病，E-mail: jiahonghong523645@163.com。
通讯作者：李红莉（1987-），女，硕士研究生，主治医师，研究方向：肾病，E-mail: 390119793@qq.com。
更新日期/Last Update: 2024-11-15